DR.R. NAVEENA,DR. YOGALAKSHMI,DR.J. BHUVANESWARRI
DOI: https://doi.org/Background: Chronic Kidney Impairment is a multifaceted pathology marked by procceding renal aberrations and varied adversities, including a paradoxical predisposition to both myriad of coagulation diseases. Thrombocytes designated for the role of hemostasis, has emerged as key modulators of inflammation, vascular integrity, and immune responses in Varying Kidney diseases and Inflammation. In CKD not only the biochemical but hematological parameters are also deranged, mainly platelet Indices thus necessitating the need for this investigation.
Objective: This investigation aims to elucidate the molecular and functional dysregulation of platelets in CKD, explore their diagnostic utility, and evaluate therapeutic challenges.
Methods: This prospective observational study was undertaken from January 2025 to June 2025 (6 months), focusing on adult patients diagnosed with CKD stages 3–5 (n-120). Recent transfusions or antiplatelet/anticoagulant therapy within 2 weeks were excluded from the study and Age ≥18 years, confirmed diagnosis based on eGFR <60 mL/min/1.73 m² for ≥3 months) and no recent history of active bleeding, thrombocytopenia (<100,000/µL), or concurrent use of anticoagulants were included in the investigation. Detailed medical proforma was collected for all participants and appropriate investigations performed on both the groups and data represented and analyzed for correlation.
Results: CKD is associated with aberrant platelet reactivity, characterized by impaired adhesion and granule release, heightened inflammatory signaling, and altered expression of surface glycoproteins. These changes contribute to vascular remodeling, atherogenesis, and renal fibrosis. Diagnostic indices show variable correlation with CKD severity, though their clinical utility remains underexplored. Therapeutic modulation of platelet function—particularly via antiplatelet agents—poses a clinical dilemma due to the dual risk of hemorrhagic and thrombotic events.
Conclusion: Thrombocytes play a pivotal yet undervalued part in the pathophysiology of CKD. A deeper understanding of their molecular dysregulation may inform biomarker development and guide precision-based therapeutic strategies. Future research is warranted for more better understanding of the disease and develop prognostic markers to timely diagnose the ailments.
